Status:
UNKNOWN
Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study
Lead Sponsor:
Shenzhen People's Hospital
Conditions:
Lipid Metabolism
Cardiovascular Diseases
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL) cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events...
Eligibility Criteria
Inclusion
- New diagnosis ACS patient by serum biomarker and coronary arteriography.
Exclusion
- Severe renal dysfunction acute or chronic bacterial and viral infections sleep apnea cancer
Key Trial Info
Start Date :
April 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 23 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04730648
Start Date
April 22 2021
End Date
April 23 2023
Last Update
May 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tangzhiming Li
Shenzhen, Guangdong, China, 518020